Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Farampator (CX-691) 是 AMPA 受体正调节剂。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 298 | 现货 | ||
2 mg | ¥ 428 | 现货 | ||
5 mg | ¥ 729 | 现货 | ||
10 mg | ¥ 980 | 现货 | ||
25 mg | ¥ 1,980 | 现货 | ||
50 mg | ¥ 3,320 | 现货 | ||
100 mg | ¥ 4,880 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 803 | 现货 |
产品描述 | Farampator (CX-691) (CX-691;Org24448) is a positive modulator of AMPA receptor. |
体外活性 | CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.). Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Furthermore, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs. Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. |
体内活性 | Farampator has potential in treating disorders characterised by cognitive deficits such as Alzheimer's disease and schizophrenia. CX691 attenuates a scopolamine-induced impairment of cued fear conditioning following acute administration (0.1 mg/kg p.o.) and a temporally induced deficit in novel object recognition following both acute (0.1 and 1.0 mg/kg p.o.) and sub-chronic (bi-daily for 7 days) administration (0.01, 0.03, 0.1 mg/kg p.o.). It also improves attentional set-shifting following sub-chronic administration (0.3 mg/kg p.o.)[1]. Farampator (500 mg) unequivocally improves short-term memory but appeares to impair episodic memory. Besides, it tends to decrease the number of switching errors in the CTMT. Drug-induced side effects (SEs) included headache, somnolence and nausea. Subjects with SEs has significantly higher plasma levels of farampator than subjects without SEs[2]. |
别名 | Org24448, CX-691 |
分子量 | 231.25 |
分子式 | C12H13N3O2 |
CAS No. | 211735-76-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (216.21 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 4.3243 mL | 21.6216 mL | 43.2432 mL | 108.1081 mL |
5 mM | 0.8649 mL | 4.3243 mL | 8.6486 mL | 21.6216 mL | |
10 mM | 0.4324 mL | 2.1622 mL | 4.3243 mL | 10.8108 mL | |
20 mM | 0.2162 mL | 1.0811 mL | 2.1622 mL | 5.4054 mL | |
50 mM | 0.0865 mL | 0.4324 mL | 0.8649 mL | 2.1622 mL | |
100 mM | 0.0432 mL | 0.2162 mL | 0.4324 mL | 1.0811 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Farampator 211735-76-1 Membrane transporter/Ion channel Neuroscience GluR iGluR inhibit Org 24448 Org-24448 Org24448 Inhibitor CX 691 CX691 Ionotropic glutamate receptors CX-691 inhibitor